Ebrahim Variava to Treatment Outcome
This is a "connection" page, showing publications Ebrahim Variava has written about Treatment Outcome.
Connection Strength
0,614
-
Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series. J Acquir Immune Defic Syndr. 2017 08 15; 75(5):577-579.
Score: 0,117
-
A randomized trial for combination nicotine replacement therapy for smoking cessation among people with HIV in a low-resourced setting. AIDS. 2025 Apr 01; 39(5):526-534.
Score: 0,049
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
Score: 0,047
-
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022 09 01; 387(9):810-823.
Score: 0,042
-
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet HIV. 2022 09; 9(9):e638-e648.
Score: 0,042
-
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB. Int J Tuberc Lung Dis. 2021 04 01; 25(4):305-314.
Score: 0,038
-
The Manipulation of the Lipid Mediator Metabolism as Adjunct Host-Directed Therapy in Tuberculosis. Front Immunol. 2021; 12:623941.
Score: 0,038
-
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. BMC Infect Dis. 2021 Jan 04; 21(1):5.
Score: 0,037
-
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019 12; 7(12):1048-1058.
Score: 0,034
-
Intensified household contact tracing, prevention and treatment support versus enhanced standard of care for contacts of tuberculosis cases in South Africa: study protocol for a household cluster-randomised trial. BMC Infect Dis. 2019 Oct 12; 19(1):839.
Score: 0,034
-
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019 03; 7(3):249-259.
Score: 0,032
-
High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J. 2018 12; 52(6).
Score: 0,032
-
Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis. 2015 Aug; 19(8):979-85.
Score: 0,025
-
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747.
Score: 0,025
-
Predictors of delay in the diagnosis and treatment of suspected tuberculosis in HIV co-infected patients in South Africa. Int J Tuberc Lung Dis. 2013 Sep; 17(9):1199-205.
Score: 0,022